PRMT5 and neoplasm: Using a systematic in vitro and in vivo approach to analyze the contribution of PRMT5 to BCSC function, we found that PRMT5 depletion in established estrogen receptor (ER)+ xenografts not only reduced tumor growth but substantially reduced the proportion of BCSCs after serial transplantation.